We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

54 hedge funds and large institutions have $39.8M invested in Insight Molecular Diagnostics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $25K | Put options by funds: $9K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

8% more funds holding

Funds holding: 50 → 54 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 1.55% → 1.54% (-0.02%)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

38% less capital invested

Capital invested by funds: $63.7M → $39.8M (-$23.9M)

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
14
Reduced
15
Closed
14
Calls
$25K
Puts
$9K
Net Calls
+$16K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.94M
2
State Street
State Street
Massachusetts
+$1.46M
3
MS
Maven Securities
Jersey
+$896K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$651K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$533K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$5.09M
2
SSA
Schonfeld Strategic Advisors
New York
-$2.82M
3
Deutsche Bank
Deutsche Bank
Germany
-$717K
4
EI
EAM Investors
California
-$670K
5
Millennium Management
Millennium Management
New York
-$579K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$20.2M – – –
EMFAT
2
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.93M -$456K -5,491 -4%
BlackRock
3
BlackRock
New York
$3.87M +$5.94M +71,415 +1,136%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.52M +$651K +7,825 +12%
State Street
5
State Street
Massachusetts
$877K +$1.46M +17,616 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$760K +$533K +6,410 +72%
MS
7
Maven Securities
Jersey
$550K +$896K +10,776 New
SSA
8
Schonfeld Strategic Advisors
New York
$474K -$2.82M -33,915 -78%
MHP
9
Manatuck Hill Partners
Connecticut
$472K -$224K -2,690 -22%
BCM
10
Bridgeway Capital Management
Texas
$424K -$103K -1,235 -13%
N
11
Nuveen
North Carolina
$246K +$410K +4,935 New
Millennium Management
12
Millennium Management
New York
$222K -$579K -6,965 -61%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$194K +$242K +2,912 +299%
Northern Trust
14
Northern Trust
Illinois
$184K +$75.2K +905 +32%
Jane Street
15
Jane Street
New York
$178K +$247K +2,969 +496%
Ameriprise
16
Ameriprise
Minnesota
$168K – – –
Charles Schwab
17
Charles Schwab
California
$145K +$186K +2,234 +337%
DAM
18
Doheny Asset Management
California
$142K +$238K +2,857 New
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$132K +$99.2K +1,193 +82%
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$100K +$166K +2,000 New
Wells Fargo
21
Wells Fargo
California
$95K +$158K +1,900 +95,000%
AG
22
Algert Global
California
$90K +$150K +1,808 New
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$87K +$21.6K +260 +17%
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$82K +$138K +1,655 New
Morgan Stanley
25
Morgan Stanley
New York
$81K -$40.7K -490 -23%
1
2 3

IMDX Hedge Fund Activity: Q2 2019 in Review

54 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2019, worth a combined $39.8M — down 38% from $63.7M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IMDX positions and 14 closed out — a net gain of 4 holders — while 14 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $5.94M. The largest seller was RTW Investments, exiting entirely with an estimated $5.09M sold.

  • 54 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2019, up from 50 in Q1 2019.
  • Funds reported $39.8M of Insight Molecular Diagnostics stock for Q2 2019, down 38% quarter-over-quarter.
  • 18 funds opened new Insight Molecular Diagnostics positions in Q2 2019 and 14 closed out, a net change of +4 holders.
  • The largest Insight Molecular Diagnostics buyer in Q2 2019 was BlackRock, an estimated $5.94M added.
  • The largest Insight Molecular Diagnostics seller in Q2 2019 was RTW Investments, an estimated $5.09M sold.

Based on aggregated 13F filings for Q2 2019.